Therapeutic agent for tumors identified by phosphorylation of proto-oncogene protein belonging to VAV family
US11058685B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 2019 |
| Grant date | Jul 13, 2021 |
| Priority date | — |
| Expiry date | Apr 24, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a therapeutic agent and others for various tumors including angioimmunoblastic T-cell lymphoma (AITL), which is an orphan disease. The present invention relates to a therapeutic agent and others for tumors identified by phosphorylation of a proto-oncogene protein belonging to the VAV family, which comprises dasatinib or a prodrug thereof or a pharmacologically acceptable salt thereof or a hydrate or solvate thereof as an active ingredient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.